<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">34596257</PMID><DateRevised><Year>2021</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2021</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Surveillance genome sequencing reveals multiple SARS-CoV-2 variants circulating in central Texas, USA, with a predominance of delta variant and review of vaccine breakthrough cases.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.27373</ELocationID><Abstract><AbstractText>As surges in the COVID-19 pandemic have continued worldwide, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has mutated, spawning several new variants, and impacting, to various degrees, transmission, disease severity, diagnostics, therapeutics, and natural and vaccine-induced immunity. Baylor Scott &amp; White Health has implemented, along with laboratory diagnosis, SARS-CoV-2 sequencing to identify variants in its geographical service area. We analyzed virus sequencing results of specimens collected across Central Texas and found dramatic changes in variant distribution in the first half of 2021. The alpha variant (B 1.1.7) became predominant at week 13 and continued dominance until week 25. A growth rate of 1.20 (R<sup>2</sup>  = 0.92) for the first 15 weeks was noted and this growth gradually declined to -0.55 (R<sup>2</sup>  = 0.99) for the final 13 weeks. Currently, B.1.1.7 is being displaced with B.1.617.2 at a 0.58 growth rate (R<sup>2</sup>  = 0.97). We also investigated vaccine breakthrough cases (VBCs) within our healthcare system and present clinical data on 28 symptomatic patients.</AbstractText><CopyrightInformation>© 2021 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mutnal</LastName><ForeName>Manohar B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-0452-7382</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Baylor Scott &amp; White Medical Center, Temple, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Shelby</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Baylor Scott &amp; White Medical Center, Temple, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohamed</LastName><ForeName>Nada</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Baylor Scott &amp; White Medical Center, Temple, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abddelgader</LastName><ForeName>Rasha</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Baylor Scott &amp; White Medical Center, Temple, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Linden</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Baylor Scott &amp; White Medical Center, Temple, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volz</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Baylor Scott &amp; White Medical Center, Temple, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Baylor Scott &amp; White Medical Center, Temple, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arroliga</LastName><ForeName>Alejandro C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine and Critical Care and Chief Medical Officer, Baylor Scott &amp; White Medical Center, Temple, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Arundhati</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Baylor Scott &amp; White Medical Center, Temple, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">disease control</Keyword><Keyword MajorTopicYN="N">genetic variation</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">vaccines/vaccine strains</Keyword><Keyword MajorTopicYN="N">virus classification</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>09</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>08</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>09</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>1</Day><Hour>8</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34596257</ArticleId><ArticleId IdType="doi">10.1002/jmv.27373</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Center for Systems Science and Engineering at Johns Hopkins University. COVID-19 Dashboard. Accessed May 3, 2021. https://coronavirus.jhu.edu/map.html</Citation></Reference><Reference><Citation>Sanyaolu A, Okorie C, Marinkovic A, et al. The emerging SARS-CoV-2 variants of concern. Ther Adv Infect Dis. 2021;8:20499361211024372.</Citation></Reference><Reference><Citation>Aleem A, Akbar Samad AB, Slenker AK. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)StatPearls. StatPearls Publishing; 2021.</Citation></Reference><Reference><Citation>Wang R, Chen J, Gao K, Wei G-W. Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries. Genomics. 2021;113:2158-2170.</Citation></Reference><Reference><Citation>Effectiveness of Covid-19. Vaccines against the B.1.617.2 (Delta) Variant | NEJM.</Citation></Reference><Reference><Citation>Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with sars-cov-2 variants. N Engl J Med. 2021;384:2212-2218.</Citation></Reference><Reference><Citation>Dolan PT, Whitfield ZJ, Andino R. Mapping the evolutionary potential of RNA viruses. Cell Host Microbe. 2018;23:435-446.</Citation></Reference><Reference><Citation>Liu Z, VanBlargan LA, Bloyet L-M, et al. Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. bioRxiv. 2021. doi:10.1101/2020.11.06.372037</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Breakthrough Case Investigations and Reporting. 2021. Accessed May 3, 2021. https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html</Citation></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603-2615.</Citation></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403-416.</Citation></Reference><Reference><Citation>Bolze A, Cirulli ET, Luo S, et al. Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States. medRxiv. 2021. doi:10.1101/2021.06.20.21259195</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. 2020. COVID Data Tracker. 2020. Accessed May 3, 2021. https://covid.cdc.gov/covid-data-tracker/#datatracker-home</Citation></Reference><Reference><Citation>Paul P, France AM, Aoki Y, et al. Genomic surveillance for SARS-CoV-2 variants circulating in the United States, December 2020-May 2021. MMWR Morb Mortal Wkly Rep. 2021;70:846-850.</Citation></Reference><Reference><Citation>Abbot G. &amp; Executive Order GA 34: Relating to the opening of Texas in response to the COVID-19 disaster. Accessed May 3, 2021. https://open.texas.gov/uploads/files/organization/opentexas/EO-GA-34-opening-Texas-response-to-COVID-disaster-IMAGE-03-02-2021.pdf</Citation></Reference><Reference><Citation>Texas Department of State Health Services. COVID-19 in Texas (Dashboard). 2021. Accessed May 3, 2021. https://txdshs.maps.arcgis.com/apps/dashboards/ed483ecd702b4298ab01e8b9cafc8b83</Citation></Reference><Reference><Citation>Texas Department of State Health Services. COVID-19 in Texas - Texas Tests and Hospitals (Dashboard). Accessed May 3, 2021. https://txdshs.maps.arcgis.com/apps/dashboards/0d8bdf9be927459d9cb11b9eaef6101f</Citation></Reference><Reference><Citation>Butt AA, Khan T, Yan P, Shaikh OS, Omer SB, Mayr F. Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination. J Infect. 2021;83:237-279. doi:10.1016/j.jinf.2021.05.021</Citation></Reference><Reference><Citation>Jain VK, Iyengar KP, Ish P. Elucidating causes of COVID-19 infection and related deaths after vaccination. Diabetes Metab Syndr. 2021;15:102212.</Citation></Reference><Reference><Citation>CDCMMWR. COVID-19 vaccine breakthrough infections reported to CDC-United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(21):792-793.</Citation></Reference><Reference><Citation>Workbook: COVID-19 Vaccine in Texas (Dashboard).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>